Keros Therapeutics logo

Keros Therapeutics share price today

(KROS)

Keros Therapeutics share price is $15.64 & ₹1,342.07 as on 7 Jan 2025, 2.30 'hrs' IST

$15.64

-0.46

(-2.86%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Keros Therapeutics share price in Dollar and Rupees. Guide to invest in Keros Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Keros Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Keros Therapeutics share price movements

  • Today's Low: $15.59
    Today's High: $16.45

    Day's Volatility :5.24%

  • 52 Weeks Low: $15.33
    52 Weeks High: $73.00

    52 Weeks Volatility :79.0%

Keros Therapeutics Returns

PeriodKeros Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-73.02%
-8.4%
0.0%
6 Months
-62.33%
-3.8%
0.0%
1 Year
-68.57%
-0.1%
0.0%
3 Years
-68.89%
2.9%
-19.8%

Keros Therapeutics Key Statistics

in dollars & INR

Previous Close
$16.1
Open
$16.47
Today's High
$16.4514
Today's Low
$15.59
Market Capitalization
$641.2M
Today's Volume
$742.1K
52 Week High
$73.0
52 Week Low
$15.33
Revenue TTM
$651.0K
EBITDA
$-202.9M
Earnings Per Share (EPS)
$-5.22
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-43.82%

How to invest in Keros Therapeutics from India?

It is very easy for Indian residents to invest directly in Keros Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Keros Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Keros Therapeutics or KROS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Keros Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Keros Therapeutics shares which would translate to 0.055 fractional shares of Keros Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Keros Therapeutics, in just a few clicks!

Returns in Keros Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Keros Therapeutics investment value today

Current value as on today

₹33,752

Returns

₹66,248

(-66.25%)

Returns from Keros Therapeutics Stock

₹69,471 (-69.47%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Keros Therapeutics

4700.0%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Investment in Keros Therapeutics from India has grown in the last 30 days as on Jan 7, 2025. 4700.0% more purchase transactions for Keros Therapeutics in the last 30 days versus the previous period.

5200%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Keros Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 5200% more investors are searching Keros Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Keros Therapeutics

  • FMR Inc

    12.09%

  • BlackRock Inc

    6.20%

  • Alkeon Capital Management, LLC

    4.68%

  • Vanguard Group Inc

    4.58%

  • Darwin Global Management, Ltd.

    3.76%

  • T. Rowe Price Associates, Inc.

    3.74%

Analyst Recommendation on Keros Therapeutics

Buy

    93%Buy

    6%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Keros Therapeutics(by analysts ranked 0 to 5 stars)

Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Keros Therapeutics

What analysts predicted

Upside of 178.42%

Current:

$15.64

Target:

$43.55

Insights on Keros Therapeutics

  • Price Movement

    In the last 1 month, KROS stock has moved down by -77.0%
  • KROS vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 90.3%
  • KROS vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 125.8%
  • Price to Sales

    ForKROS every $1 of sales, investors are willing to pay $847.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Keros Therapeutics Technicals Summary

Sell

Neutral

Buy

Keros Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Keros Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Keros Therapeutics Inc
-76.02%
-62.33%
-68.57%
-68.89%
-68.73%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Keros Therapeutics Inc
NA
NA
NA
-4.22
-0.44
-0.28
NA
13.57
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Keros Therapeutics Inc
Buy
$641.2M
-68.73%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Keros Therapeutics

keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i
Organization
Keros Therapeutics
Employees
160
CEO
Dr. Jasbir S. Seehra Ph.D.
Industry
Commercial Services

Management People of Keros Therapeutics

NameTitle
Dr. Jasbir S. Seehra Ph.D.
CEO & Chair of the Board
Mr. Christopher Rovaldi M.Sc.
President & COO
Mr. Keith C. Regnante MBA
Chief Financial Officer
Ms. Esther Cho J.D.
Senior VP, General Counsel & Secretary
Ms. Robin Wagner
Senior Vice President of Human Resources
Mr. John Oram M.B.A.
Senior Vice President of Program & Portfolio Management
Dr. Yung H. Chyung M.D.
Chief Medical Officer

Important FAQs about investing in Keros Therapeutics from India :

What is Keros Therapeutics share price today?

Keros Therapeutics share price today stands at $15.64, Open: $16.47 ; Previous Close: $16.10 ; High: $16.45 ; Low: $15.59 ; 52 Week High: $73.00 ; 52 Week Low: $15.33. The stock opens at $16.47, after a previous close of $16.10. The stock reached a daily high of $16.45 and a low of $15.59, with a 52-week high of $73.00 and a 52-week low of $15.33.

Can Indians buy Keros Therapeutics shares?

Yes, Indians can invest in the Keros Therapeutics (KROS) from India.

With INDmoney, you can buy Keros Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Keros Therapeutics at zero transaction cost.

How can I buy Keros Therapeutics shares from India?

It is very easy to buy Keros Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Keros Therapeutics be purchased?

Yes, you can buy fractional shares of Keros Therapeutics with INDmoney app.

What are the documents required to start investing in Keros Therapeutics stocks?

To start investing in Keros Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Keros Therapeutics

Today’s highest price of Keros Therapeutics (KROS) is $16.45.

Today’s lowest price of Keros Therapeutics (KROS) is $15.59.

What is today's market capitalisation of Keros Therapeutics

Today's market capitalisation of Keros Therapeutics KROS is 641.2M

What is the 52 Week High and Low Range of Keros Therapeutics

  • 52 Week High

    $73.00

  • 52 Week Low

    $15.33

What are the historical returns of Keros Therapeutics?

  • 1 Month Returns

    -76.02%

  • 3 Months Returns

    -62.33%

  • 1 Year Returns

    -68.57%

  • 5 Years Returns

    -68.73%

Who is the Chief Executive Officer (CEO) of Keros Therapeutics

Dr. Jasbir S. Seehra Ph.D. is the current Chief Executive Officer (CEO) of Keros Therapeutics.